Study Evaluating Safety, Tolerability and Efficacy of YM150 in Subjects With Acute Coronary Syndromes (RUBY-1)

Astellas logo

Astellas

Status and phase

Completed
Phase 2

Conditions

Acute Coronary Syndrome

Treatments

Drug: Placebo
Drug: YM150

Study type

Interventional

Funder types

Industry

Identifiers

NCT00994292
2008-005972-29 (EudraCT Number)
150-CL-201

Details and patient eligibility

About

The purpose of this study is to evaluate the safety and efficacy of various doses of YM150 (the experimental drug) in the prevention of ischemic vascular events in subjects with recent acute coronary syndromes.

Enrollment

1,276 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • has a diagnosis of STE-ACS, NSTE-ACS as index event according to accepted guidelines such as the ESC or AHA guidelines
  • has elevated cardiac biomarkers

Exclusion criteria

  • is planned for myocardial revascularization (e.g., Coronary Artery Bypass Graft (CABG) or elective or staged PCI) or any other invasive procedure with increased risk for bleeding (i.e. elective surgical procedures) within 60 days after randomization
  • has had recent stroke or TIA ≤ 12 months prior to index event
  • has persistent BP of 160 mmHg systolic or higher and/or 100 mmHg diastolic or higher at baseline with or without medication
  • has participated in another clinical trial of an investigational drug (including placebo) or device within 30 days (or the limit set by national law, whichever is longer) of signing informed consent for the present study
  • has participated in any YM150 clinical trials
  • requires ongoing parenteral or oral anticoagulant therapy
  • has active bleeding or is in the opinion of the investigator at high risk of bleeding during the study

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

1,276 participants in 7 patient groups, including a placebo group

1. YM150 Dose V, twice daily
Experimental group
Treatment:
Drug: YM150
2. YM150 Dose W, once daily
Experimental group
Treatment:
Drug: YM150
3. YM150 Dose X, twice daily
Experimental group
Treatment:
Drug: YM150
4. YM150 Dose Y, once daily
Experimental group
Treatment:
Drug: YM150
5. YM150 Dose Y, twice daily
Experimental group
Treatment:
Drug: YM150
6. YM150 Dose Z, once daily
Experimental group
Treatment:
Drug: YM150
7. Placebo
Placebo Comparator group
Treatment:
Drug: Placebo

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems